Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W; IOTN Consortium; Odunsi A. Annapragada A, et al. Among authors: fong l. J Immunother Cancer. 2020 Jun;8(1):e000796. doi: 10.1136/jitc-2020-000796. J Immunother Cancer. 2020. PMID: 32554617 Free PMC article. Review.
Immunotherapy for prostate cancer.
Fong L, Small EJ. Fong L, et al. Semin Oncol. 2003 Oct;30(5):649-58. doi: 10.1016/s0093-7754(03)00350-6. Semin Oncol. 2003. PMID: 14571412 Review.
Immunotherapy for prostate cancer.
Fong L, Small EJ. Fong L, et al. Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z. Curr Oncol Rep. 2007. PMID: 17430695 Review.
On the Verge: Immunotherapy for Colorectal Carcinoma.
Oh DY, Venook AP, Fong L. Oh DY, et al. Among authors: fong l. J Natl Compr Canc Netw. 2015 Aug;13(8):970-8. doi: 10.6004/jnccn.2015.0117. J Natl Compr Canc Netw. 2015. PMID: 26285242 Review.
Immune Checkpoint Inhibition in Prostate Cancer.
Nicholson LT, Fong L. Nicholson LT, et al. Among authors: fong l. Trends Cancer. 2020 Mar;6(3):174-177. doi: 10.1016/j.trecan.2020.01.003. Epub 2020 Feb 6. Trends Cancer. 2020. PMID: 32101720
Transcriptional mediators of treatment resistance in lethal prostate cancer.
He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. He MX, et al. Among authors: fong l. Nat Med. 2021 Mar;27(3):426-433. doi: 10.1038/s41591-021-01244-6. Epub 2021 Mar 4. Nat Med. 2021. PMID: 33664492 Free PMC article.
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. Sinha M, et al. Among authors: fong l. J Immunother Cancer. 2021 May;9(5):e002254. doi: 10.1136/jitc-2020-002254. J Immunother Cancer. 2021. PMID: 33986125 Free PMC article. Clinical Trial.
681 results